Hormone Optimization Protocol
| Category | Protocols |
|---|---|
| Also known as | GH Axis Protocol, HPG Axis Protocol, Endocrine Optimization Protocol |
| Last updated | 2026-04-14 |
| Reading time | 7 min read |
| Tags | protocolshormonesgrowth-hormonetestosteronehpg-axisgh-axisendocrine |
Overview
Hormonal decline is one of the most predictable features of aging. Growth hormone (GH) output drops approximately 14% per decade after age 30 (somatopause), testosterone declines 1–2% per year after age 30 in men (andropause), and women experience the dramatic hormonal shift of perimenopause and menopause. These changes drive progressive loss of muscle mass, bone density, cognitive function, metabolic efficiency, and recovery capacity.
This protocol addresses two primary endocrine axes: the GH axis (somatotropic axis) through growth hormone secretagogues and optimization strategies, and the HPG axis (hypothalamic-pituitary-gonadal axis) through comprehensive hormonal assessment and targeted support. The approach prioritizes stimulating endogenous production over exogenous replacement where possible, using peptides that work with the body's own feedback systems.
For growth hormone secretagogues specifically, see the GH Secretagogue Protocol. For post-cycle hormonal recovery, see the PCT Protocol. For women-specific considerations, see Female Considerations.
The GH Axis
GH Axis Overview
Growth hormone is released from the anterior pituitary in pulsatile bursts, primarily during deep sleep and in response to exercise, fasting, and specific amino acid stimuli. GH acts both directly and through insulin-like growth factor-1 (IGF-1), which is produced primarily by the liver. Together, GH and IGF-1 regulate protein synthesis, fat metabolism, bone density, immune function, and tissue repair.
The GH axis is regulated by two hypothalamic peptides: growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which inhibits it. GH secretagogue peptides work by amplifying the natural pulsatile pattern rather than creating the supraphysiological flat-line levels seen with exogenous GH injection.
GH Axis Peptides
| Peptide | Class | Mechanism | Typical Dose |
|---|---|---|---|
| CJC-1295 (no DAC) / Mod GRF 1-29 | GHRH analog | Amplifies GH-releasing signal | 100–200 mcg |
| Ipamorelin | Ghrelin mimetic (GHSP) | Stimulates GH release at pituitary | 100–200 mcg |
| GHRP-2 | Ghrelin mimetic (GHSP) | Potent GH release, some hunger/cortisol | 100–200 mcg |
| GHRP-6 | Ghrelin mimetic (GHSP) | GH release, significant hunger stimulation | 100–200 mcg |
| Tesamorelin | GHRH analog | GHRH(1-44) with trans-3-hexenoic acid | 1–2 mg daily |
| MK-677 (Ibutamoren) | Non-peptide GH secretagogue | Oral ghrelin mimetic, long-acting | 10–25 mg daily |
GH Axis Protocol
The most commonly referenced GH secretagogue combination is CJC-1295 (no DAC) paired with Ipamorelin. This pairing is preferred because it combines both arms of GH stimulation (GHRH analog + ghrelin mimetic) for synergistic effect, and Ipamorelin is the cleanest ghrelin mimetic with minimal cortisol, prolactin, or hunger effects.
Standard GH secretagogue protocol:
| Time | Peptides | Dose | Route |
|---|---|---|---|
| Pre-bed (fasting 2+ hours) | CJC-1295 no DAC + Ipamorelin | 100 mcg each | SubQ |
| Post-workout (optional, fasting) | CJC-1295 no DAC + Ipamorelin | 100 mcg each | SubQ |
Timing rules:
- Administer on an empty stomach (2+ hours after eating, 30+ minutes before eating)
- Food — especially carbohydrates and fats — blunts GH release
- The pre-bed dose aligns with the natural nocturnal GH pulse
- Post-workout dosing capitalizes on exercise-stimulated GH release
Cycling: 5 days on / 2 days off, or 8–12 weeks on / 4 weeks off. See GH Secretagogue Protocol and Peptide Cycling for detailed cycling strategies.
See GH/IGF-1 Research for the scientific background on growth hormone biology.
The HPG Axis
HPG Axis Overview
The hypothalamic-pituitary-gonadal axis controls sex hormone production. GnRH (gonadotropin-releasing hormone) from the hypothalamus stimulates LH and FSH from the pituitary, which in turn stimulate testosterone production in the testes (or estrogen/progesterone from the ovaries). Negative feedback loops maintain homeostasis — but these systems can be disrupted by age, obesity, chronic stress, poor sleep, and exogenous hormone use.
HPG Axis Assessment
Before any hormonal intervention, comprehensive testing is essential:
Male panel:
| Test | Target Range | Notes |
|---|---|---|
| Total testosterone | 500–900 ng/dL | Morning draw (before 10 AM) |
| Free testosterone | 15–25 pg/mL | Calculated or equilibrium dialysis |
| SHBG | 20–50 nmol/L | High SHBG reduces free T |
| Estradiol (sensitive) | 20–35 pg/mL | Not standard estradiol assay |
| LH and FSH | Normal ranges | Differentiate primary vs secondary hypogonadism |
| Prolactin | < 20 ng/mL | Elevated prolactin suppresses GnRH |
| DHT | Normal range | 5-alpha reductase activity |
| IGF-1 | Age-appropriate upper quartile | GH axis status |
Female panel: See Female Considerations for comprehensive hormone testing in women, including estradiol, progesterone, testosterone, DHEA-S, and thyroid assessment across the menstrual cycle or in post-menopause.
See Blood Work Monitoring for drawing protocols and lab recommendations.
Natural HPG Optimization
Before peptide or hormonal interventions, optimize the fundamentals that directly impact HPG axis function:
- Sleep: Testosterone production is strongly correlated with sleep quality and duration. Most testosterone is produced during REM sleep. See Sleep Optimization Protocol.
- Body composition: Adipose tissue aromatizes testosterone to estrogen. Reducing excess body fat directly improves the testosterone-to-estrogen ratio. See Fat Loss Protocol.
- Stress management: Chronic cortisol elevation directly suppresses GnRH and LH. The stress-hormone axis and reproductive axis compete for shared precursors.
- Resistance training: Heavy compound movements (squats, deadlifts, presses) acutely elevate testosterone and growth hormone. Chronic training improves baseline levels.
- Micronutrient optimization:
| Nutrient | Dose | Role |
|---|---|---|
| Zinc | 30–50 mg/day | Direct role in testosterone synthesis and aromatase inhibition |
| Vitamin D3 | 5,000 IU/day | Correlates with testosterone levels; dose to blood level |
| Magnesium | 400 mg/day | Increases free testosterone by reducing SHBG binding |
| Boron | 6–10 mg/day | May increase free testosterone and reduce SHBG |
| Ashwagandha (KSM-66) | 600 mg/day | Clinical evidence for modest testosterone increase and cortisol reduction |
Peptide Support for HPG Axis
Kisspeptin, the hypothalamic peptide that triggers GnRH release, represents an emerging research area for HPG axis stimulation. Research has demonstrated that kisspeptin administration can stimulate LH and testosterone production, but this remains primarily in the clinical research phase.
Gonadorelin (GnRH analog):
- Used in some protocols alongside testosterone replacement therapy (TRT) to maintain testicular function and fertility
- Typical dose: 100–200 mcg subcutaneous 2–3x per week
- Mimics the natural pulsatile GnRH signal
Integrated Protocol
Comprehensive daily protocol for men over 35:
| Time | Intervention | Details |
|---|---|---|
| Morning | Vitamin D3 5,000 IU + Zinc 30 mg + Boron 6 mg | With breakfast |
| Morning | Resistance training (3–4x/week) | Compound movements, progressive overload |
| Post-workout (fasting) | CJC-1295 no DAC + Ipamorelin 100 mcg each | Optional; SubQ |
| Evening | Magnesium glycinate 400 mg | 1 hour before bed |
| Pre-bed (fasting 2+ hours) | CJC-1295 no DAC + Ipamorelin 100 mcg each | Primary GH secretagogue dose |
| Ongoing | Sleep optimization | 7–9 hours; see Sleep Optimization Protocol |
Blood work schedule:
- Baseline comprehensive panel before starting
- Follow-up at 6 weeks (check IGF-1 for GH axis response)
- Quarterly comprehensive panels ongoing
Important Considerations
- Medical supervision for hormonal interventions: Hormone optimization should involve a healthcare provider experienced in endocrinology or anti-aging medicine.
- GH axis caution: Excessive GH/IGF-1 elevation is associated with increased cancer risk in epidemiological studies. The goal is optimization to youthful physiological levels, not supraphysiological elevation.
- Insulin sensitivity: GH is a counter-regulatory hormone that can impair glucose tolerance. Monitor fasting glucose and HbA1c, particularly with higher-dose or longer-duration GH secretagogue use. MK-677 is particularly notable for insulin resistance effects.
- Not a substitute for TRT: For men with clinically diagnosed hypogonadism (total T consistently below 300 ng/dL with symptoms), peptide-based approaches may be insufficient. TRT may be medically indicated. Peptides work best for optimization of functioning — but suboptimal — hormonal axes.
- Female application: Women can benefit from GH secretagogues at the same doses. HPG axis optimization in women is more complex and should always involve a provider familiar with female endocrinology. See Female Considerations.
- Quality and sourcing: See Purity and Testing.
Disclaimer
This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.
Related entries
- Anti-Aging Protocol— A protocol combining Epithalon, GHK-Cu, and MOTS-c for anti-aging research, covering telomere maintenance, skin and tissue rejuvenation, and mitochondrial optimization strategies.
- Female-Specific Considerations— An overview of peptide considerations specific to female physiology, including hormonal cycle timing, pregnancy contraindications, dosing adjustments, and compounds of particular relevance to women.
- GH Secretagogue Protocol— A detailed protocol for combining Ipamorelin with CJC-1295 (or Mod GRF 1-29) to stimulate natural growth hormone release, including timing, fasted administration requirements, and cycling strategies.
- Over-40 Optimization Protocol— A peptide protocol framework designed for individuals over 40, addressing age-related growth hormone decline, recovery slowdown, joint deterioration, and metabolic changes with targeted compound selection and conservative dosing strategies.
- Post-Cycle Therapy (PCT)— A protocol for post-cycle therapy using Gonadorelin, Kisspeptin, and Enclomiphene to support HPG axis recovery after anabolic suppression, including timing, phased approaches, and monitoring.